On site, the nanodrug leaves anti-PD-1 mAb to block PD-1 on anti-tumor T cells and generates a new curcumin-encapsulated nanodrug that can be taken up by tumor cells or tumor associated macrophages [122]. This evidence concerns the gene PDCD1 and neoplasm.